GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations

Christopher T Richlin¹, April Armstrong¹, Hanna Johnsson¹+1

• ¹As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; A. Armstrong, MD, PhD, University of Southern California, Los Angeles, California, USA; H. Johnsson, MD University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK; M.L. Mulder, MD, Resident of Rheumatology, Department of Rheumatology, Sint Maartenskliniek, and Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands. AA has received research funding from Boehringer Ingelheim/Parexel, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Galderma, Janssen Ortho Inc., Kyowa Hakko Kirin, Leo Pharma, Pfizer Inc., Sanofi Genzyme, UCB Pharma; and honorariums from AbbVie, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Leo Pharma, Modernizing Medicine, Novartis Pharmaceuticals Corp., Ortho Dermatologics, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, and Sun Pharma. CTR, HJ, and MLM declare no conflicts of interest. This paper does not require institutional review board approval. Address correspondence to Dr. C.T. Ritchlin, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA.